Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
      • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL

    September 2019

  • New Prognostic System for Patients with Relapsed Follicular Lymphoma

    May 2018

  • Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT

    May 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • NHL
  • Email
  • Print This Page

Related Resources

  • Subscribe to the Latest NHL Research
  • HCT Guidelines App

Patient Resources

  • Transplant and NHL (PDF)
  • Transplant Outcomes and Treatment Decisions
  • Transplant Basics Booklet
  • Transplant Basics Videos

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphomas (NHL) are a highly heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer (NK) cells. In the United States, B-cell NHL represents 80-85% of cases; T-cell NHL, 15-20%; and NK NHL is rare. Most hematopoietic cell transplantation (HCT) performed for NHL is autologous, but in some cases, physicians may perform allogeneic HCT for particularly high-risk relapsed or refractory disease. [1, 2]

Figure 1 shows the increase by age group in the number of unrelated donor transplants facilitated by the National Marrow Donor Program® (NMDP)/Be The Match® for adults with NHL between 2008 and 2016.

Figure 1. Unrelated Donor HCT in Adult NHL

Unrelated Donor HCT in Adult NHL

Download slide "Unrelated Donor HCT in Adult NHL"


Advances

The outlook for patients with NHL has steadily improved over the last decade due to several clinical advances, including:

  • Increased use of reduced-intensity conditioning regimens for older patients and those with comorbidities to reduce transplant-related mortality
  • More refined prognostication using clinical factors and/or molecular techniques to ascertain which patients would benefit most from transplantation [3,4]
  • New research indicating that autologous or reduced-intensity allogeneic HCT is beneficial in chemotherapy-sensitive patients with mantle cell lymphoma. [5]

Outcomes

Improved Survival


Figure 2. NHL Survival Over Time, Unrelated HCT, with No Prior Autologous HCT

One- and two-year overall survival in adult NHL, allogeneic unrelated transplants facilitated by NMDP/Be The Match, with no prior autologous HCT.

133_nhl

Download slide "NHL Survival Over Time, Unrelated HCT, with No Prior Autologous HCT"

Figure 3.

One- and two-year overall survival in adult NHL, allogeneic unrelated transplants facilitated by NMDP/Be The Match, with prior autologous HCT.

NHL Survival Over Time, Unrelated HCT - with prior autologous HCT

Download slide "NHL Survival Over Time, Unrelated HCT, with Prior Autologous HCT"

Allogeneic and Autologous Transplant Outcomes

Review outcomes for allogeneic and autologous transplantation in patients with NHL below. View additional NHL slides showing demographic data and transplant trends. Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research®), our research program.

Figure 4. NHL Survival, Unrelated Marrow HCT, by Disease Status

NHL Survival, Unrelated Marrow HCT, By Disease Status

Download slide "NHL Survival, Unrelated Marrow HCT, by Disease Status"

Figure 5. NHL Survival, Unrelated PBSC HCT, by Disease Status

NHL Survival, Unrelated PBSC HCT, By Disease Status

Download slide "NHL Survival, Unrelated PBSC HCT, by Disease Status"

Figure 6. NHL Survival, Unrelated HCT, Non-Myeloablative, by Cell Source

NHL Survival, Unrelated HCT, Non-Myeloablative, By Cell Source

Download slide "NHL Survival, Unrelated HCT, Non-Myeloablative, by Cell Source"

Figure 7. NHL Survival, HCT using RIC/Non-Myeloablative Preparative Regimen, with Prior Autologous HCT, by Cell Source

NHL Survival, HCT using RIC/Non-Myeloablative Preparative Regimen, with Prior Autologous HCT, by Cell Source

Download slide "NHL Survival, HCT using RIC/Non-Myeloablative Preparative Regimen, with Prior Autologous HCT, by Cell Source"

Figure 8. NHL Survival, Unrelated Marrow HCT, with Prior Autologous HCT, by Disease Status

NHL Survival, Unrelated Marrow HCT, with Prior Autologous HCT, by Disease Status

Download slide "NHL Survival, Unrelated Marrow HCT, with Prior Autologous HCT, by Disease Status"

Figure 9. NHL Survival, Unrelated PBSC HCT, with Prior Autologous HCT, by Disease Status

NHL Survival, Unrelated PBSC HCT, with Prior Autologous HCT, by Disease Status

Download slide "NHL Survival, Unrelated PBSC HCT, with Prior Autologous HCT, by Disease Status"

Figure 10. Diffuse Large B-Cell Lymphoma Survival, Autologous HCT, by Disease Status

Diffuse Large B-Cell Lymphoma Survival, Autologous HCT, By Disease Status

Download slide "Diffuse Large B-Cell Lymphoma Survival, Autologous HCT, by Disease Status"

Figure 11. Diffuse Large B-Cell Lymphoma Survival, Sibling HCT, by Disease Status

Diffuse Large B-Cell Lymphoma Survival, Sibling HCT, By Disease Status

Download slide "Diffuse Large B-Cell Lymphoma Survival, Sibling HCT, by Disease Status"

Figure 12. Follicular Lymphoma Survival, By Disease Status and Donor Type

Funicular Lymphoma Survival, By Disease Status and Donor Type

Download slide "Follicular Lymphoma Survival, By Disease Status and Donor Type"

Figure 13. Follicular Lymphoma Survival, Autologous HCT, by Disease Status

Follicular Lymphoma Survival, Autologous HCT, By Disease Status

Download slide "Follicular Lymphoma Survival, Autologous HCT, by Disease Status"

Figure 14. Mantle Cell Lymphoma Survival, HCT, by Donor Type

Mantle Cell Lymphoma Survival, HCT, By Donor Type

Download slide "Mantle Cell Lymphoma Survival, HCT, by Donor Type"

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [5]

Transplant Consultation Guidelines: NHL

Follicular Lymphoma

  • Poor response to initial treatment
  • Initial remission duration <24 months
  • First relapse
  • Transformation to diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma

  • Primary induction failure, including residual PET avid disease
  • First relapse
  • CR2 or subsequent remission
  • Double or triple hit (MYC and BCL-2 and/or BCL-6) – at diagnosis
  • Primary CNS lymphoma at diagnosis PIF or first relapse

High Grade B-Cell Lymphoma

  • MYC and BCL-2 and/or BCL-6 rearrangements
  • Primary induction failure
  • CR1
  • First relapse
  • CR2 or subsequent remission

Mantle T-Cell Lymphoma

  • At diagnosis
  • First relapse
  • Bruton's tyrosine kinase (BTK) intolerant or resistant disease 

Mature T-Cell Lymphoma

  • CR1
  • First relapse

Other High-Risk Lymphomas

  • At diagnosis 

Download as a slide
View complete Referral Timing Guidelines

 

CAR T Cell Therapy Video for Patients

In this easy-to-understand video, Linda J. Burns, M.D., Vice President, Health Services Research, and Scott Kerwin, R.N., M.N., C.C.R.C., C.C.R.N., Clinical Trial Patient Education Specialist, explain what CAR T cell therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more. 

In this easy-to-understand video, Linda J. Burns, M.D., Vice President, Health Services Research, and Scott Kerwin, R.N., M.N., C.C.R.C., C.C.R.N., Clinical Trial Patient Education Specialist, explain what CAR T cell therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more. View the video and share it with patients and caregivers who are looking for information on CAR T therapy as a treatment option.

References

  1. NCCN Guidelines Version 3.2018 B- and T-Cell Lymphomas. Access B-cell guidelines (PDF)• ••• Access T-cell guidelines (PDF)
  2. Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia. 2014; 28(11): 2117-2130. Access
  3. Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: An evidence-based review. Biol Blood Marrow Transplant. 2010; 16(4): 443-468. Access
  4. Sureda A, Zhang M-J, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018; 124(8): 1733-1742. Access
  5. Fenske TS, Zhang M-J, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality. J Clin Oncol. 2014; 32(4): 273-281. Access
  6. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright